2022-03-14

Adlai Nortye Announces Appointment of Dr. Victoria Demby as Senior Vice President of Global Regulatory Affairs

2022-02-16

Adlai Nortye Announces Publication of Preclinical Research of AN3025 (anti-hTNFR2）in Frontiers in Immunology

2022-01-26

Adlai Nortye Announces Global License-out Agreement with Biotime for Several Products Including PD-L1 Inhibitor (AN4005) and Anti-hTNFR2 Antibody (AN3025)

2022-01-06

Adlai Nortye Announces First Patient Dosed in Phase I Clinical Trial of the orally available, small-molecule PD-L1 inhibitor AN4005 for Advanced Tumors

2021-10-14

Oncolytics Biotech®Partner Adlai Nortye Doses First Patient in Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer

2021-09-08

Adlai Nortye Announces First Patient Dosed in Phase Ia Clinical Trial of AN2025 and AN0025 in Combination with atezolizumab for Advanced Solid Tumors

2021-04-15

Adlai Nortye Announces First Patient Dosed in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

2021-04-13

Adlai Nortye Presents Early Pre-Clinical Data on its Anti-hTNFR2 (AN3025) Program at the AACR Annual Meeting 2021

2021-03-26

Adlai Nortye Congratulates Dr. Ronald M. Evans, Chair of Scientific Advisory Board, on Receipt of the 2021 Asan Award in Basic Medicine

2021-03-08

Adlai Nortye Announces Formation of its New Scientific Advisory Board

2019-09-30

Adlai Nortye Presents Encouraging Phase 1b Study Data of AN0025 at ESMO 2019

2019-03-22

Adlai Nortye Receives NMPA Approval for Pelareorep Phase III Clinical Trials